Johnson & Johnson (J&J) has agreed to work with the Indian government to offer compensation to patients who were affected by faulty hip implants.

DePuy International, a unit of J&J, sold the implant known as DePuy ASR in India before it was recalled in 2010 after data indicated they failed at a higher-than-expected rate.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Johnson & Johnson has been recommended to pay a base compensation of Rs2m ($27842) to each patient.”

Last month the Central Drugs Standard Control Organization (CDSCO) asked the company to compensate all the patients who were fitted with articular surface replacement (ASR) implant.

The government -appointed committee recommended a base compensation of Rs2m ($27842) to each patient.

It is estimated that nearly 4,500 patients were fitted with the recalled device before they were recalled.

A Johnson & Johnson spokeswoman in a statement emailed to Reuters said: “We have always been and continue to be fully committed to supporting all ASR patients in India, and the rest of the world.

“In light of the recent committee report, we are seeking to work with the Indian government to develop an appropriate process for providing further support and compensation for patients in need,” she added.

However, there is no confirmation on whether the company will pay the recommended compensation to each patient or is in plans to negotiate the amount with the government, reported the news agency.

In 2013, Johnson & Johnson agreed to pay nearly $2.5bn in the US to settle thousands of lawsuits from patients who complained that they were affected by the implants.